Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VAR002
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VARIANT Gets EMA Positive Feedback for Innovative Gene Therapy VAR002
Details : VAR002 is a recombinant adeno-associated viral (rAAV) vector initially developed to treat Leber's congenital amaurosis, Retinitis pigmentosa, and Cone-rod dystrophy due to a mutation in the CRX gene.
Product Name : VAR002
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 03, 2025
Lead Product(s) : VAR002
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VAR002
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VAR002 is a CRX-expressing AAV vector designed as a relevant therapeutic approach for gene supplementation and a promising drug candidate for mutation-agnostic gene therapy. VAR002 prevents photoreceptor degeneration without adverse effects linked with C...
Product Name : VAR002
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 24, 2021
Lead Product(s) : VAR002
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable